Overview

Deucravacitinib in PG

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).

Phase:

Early Phase 1

Details

Lead Sponsor:

Dartmouth-Hitchcock Medical Center

Collaborator:

Bristol-Myers Squibb